Spike in Infectious Diseases to drive the Attenuated Vaccines Market, reaching US$ 9.31 Billion by the year 2032 at a CAGR of 6.8% from 2022-32

The global attenuated vaccines market was worth US$ 4.45 Billion in the year 2022 and is expected to reach US$ 9.31 Billion by the year 2032 at a CAGR of 6.8% between 2022 and 2032.

Attenuated vaccination helps in preventing ailments like yellow fever, tuberculosis, measles, retroviral, and likewise. Moreover, it has been reported that there is a re-emergence of the above-mentioned diseases with an overdose of antibiotics. This is another factor accelerating the attenuated vaccines market in the forecast period.

The present scenario is also such that pharmaceuticals are going for a number of clinical trials throughout the year. This factor is catalyzing the attenuated vaccines market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14844

Live attenuated vaccines get prepared by weakening viral or bacterial stains by making use of stable mutations. The technology does not cause microorganisms to perish; but eliminates their disease-causing ability.

At the same time, the fact that initial cost associated with development of these vaccines is high can’t be ignored. This factor could restrain the attenuated vaccines market going forward.

Future Market Insights has walked through these facts with future prospects in its latest market study entitled ‘Attenuated Vaccines Market’. It has its indigenous team of analysts and consultants to look through an eagle’s eye view in its primary, secondary, and tertiary modes of research.

“With infectious diseases on the rise, the global attenuated vaccines market is likely to grow on a stupendous note in the forecast period”, says an analyst from Future Market Insights.

Key Takeaways from Attenuated Vaccines Market

• North America holds more than 30% of the overall market share extensive research being conducted regarding treatments against infectious diseases. Additionally, the governments are taking initiatives regarding vaccination against influenza. As of May 2022, ~65% of the localites have been vaccinated.
• The Asia-Pacific is expected to grow at the quickest rate in the attenuated vaccines market going forward. This could be attributed to immunization programs being conducted on an exorbitant note in the regions like India. Herein, Mission Indradhanush is into operation since the year 2014; which does cover almost 27 Million infants every single year. As a part of this programme, novel vaccines inclusive of PCV (Pneumococcal Conjugate Vaccines) and RVV (Rotavirus Vaccines) were covered.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14844

Competitively Attenuated Vaccines

• Valneva SE, in May 2022, did announce completing lot-to-lot Phase 3 trial of VLA1553 (single-shot chikungunya live attenuated vaccines candidate). The ultimate analysis encloses 6-month follow-up data. Topline results were recorded in December 2021.
• Bavarian Nordic, in May 2022, developed Jynneos – a live attenuated vaccine that renders immunity against monkeypox and smallpox. Plus, symptoms could be managed with hydration therapy and antibiotics.
• Codagenix, Inc., in May 2022, collaborated with Serum Institute of India Pvt. Ltd. for dosing its UK-based Phase 1 clinical trial for evaluating usage of the former’s new live-attenuated, intranasal vaccine ‘CoviLiv’. It acts as a booster to healthy adults after getting vaccinated for Covid-19.

What does the Report say?

• The research study is based on vaccines type (monovalent attenuated vaccines and multivalent attenuated vaccines), by indication (attenuated vaccines for influenza, attenuated vaccines for MMR (measles, mumps & rubella), attenuated vaccines for polio, attenuated vaccines for chickenpox, attenuated vaccines for shingles, attenuated vaccines for rotavirus, and attenuated vaccines for other indications), by route of administration (intramuscular attenuated vaccines administration, subcutaneous attenuated vaccines administration, oral attenuated vaccines administration, intranasal attenuated vaccines administration, and intravenous attenuated vaccines administration), by age group (attenuated vaccines for paediatrics, attenuated vaccines for adolescents, attenuated vaccines for adults, and attenuated vaccines for geriatric patients), and by end-user (attenuated vaccines for hospitals, attenuated vaccines for clinics, and attenuated vaccines for other end-users).
• With governmental organizations emphasizing on immunization, the global attenuated vaccines market is expected to grow on a grand note going forward.

By Key Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Sanofi
• Astellas Pharma
• Johnson & Johnson
• CSL Limited
• Serum Institute of India Pvt. Ltd.

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/14844

Key Segments Covered in the Attenuated Vaccines Market Report

Attenuated Vaccines Market by Vaccines Type:

• Monovalent Attenuated Vaccines
• Multivalent Attenuated Vaccines

Attenuated Vaccines Market by Indication:

• Attenuated Vaccines for Influenza
• Attenuated Vaccines for Measles, Mumps & Rubella (MMR)
• Attenuated Vaccines for Polio
• Attenuated Vaccines for Chickenpox
• Attenuated Vaccines for Shingles
• Attenuated Vaccines for Rotavirus
• Attenuated Vaccines for Other Indications

Attenuated Vaccines Market by Route of Administration:

• Intramuscular Attenuated Vaccines Administration
• Subcutaneous Attenuated Vaccines Administration
• Oral Attenuated Vaccines Administration
• Intranasal Attenuated Vaccines Administration
• Intravenous Attenuated Vaccines Administration

Attenuated Vaccines Market by Age Group:

• Attenuated Vaccines for Pediatrics
• Attenuated Vaccines for Adolescents
• Attenuated Vaccines for Adults
• Attenuated Vaccines for Geriatric Patients

Attenuated Vaccines Market by End User:

• Attenuated Vaccines for Hospitals
• Attenuated Vaccines for Clinics
• Attenuated Vaccines for Other End Users

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs